Therapeutic | Blontuvetmab |
Target | MS4A1 |
Heavy Chain | QVQLQQSRAELVRPGASVTLSCKPSGYTFTDYEVHWVKQTPVHGLEWIGAIDPETGGTADNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCTNFVDVWGTGTTVTVSS |
Light Chain | DVVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSGNQKNYLAWYQQKPGQSPRLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVFYCQQYYNYPLTFGGGTHL |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Canine Whole mAb |
Isotype | G2 |
Highest Clinical Trial (June '19) | Unknown |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2015 |
INN Year Recommended | 2016 |
Companies Involved | Aratana Pharmaceuticals |
Conditions Approved | na |
Conditions Active | Canine B-cell lymphoma |
Conditions Discontinued | na |
Notes |